Concerning more CRC types than herein identified, a clinical interpretation of CRC entails definitions of more diverse biomarkers especially other hematopoietic or progenitor cell markers such as AC133, CD14, and CD34, as well as the establishment of robust specificity cutoffs for quantitatively analysis of CRCs on varieties of patients (48). This evidence concerns the gene CD34 and colorectal carcinoma.